Clinical Trial Update: Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity study of GSK1437173A (HZ/su) vaccine for herpes zoster completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• HZ/su vaccine GSK1437173A (HZ/su vaccine GSK1437173A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-01-06